tiprankstipranks
Corcept Therapeutics Inc. (GB:0I3Q)
LSE:0I3Q
UK Market
0I3Q
Corcept Therapeutics
RESEARCH TOOLSreports

Corcept Therapeutics (0I3Q) Share Forecast & Price Target

2 Followers
See the Price Targets and Ratings of:

0I3Q Analyst Ratings

Moderate Buy
5Ratings
Moderate Buy
4 Buy
0 Hold
1 Sell
Based on 5 analysts giving stock ratings to
Corcept
Therapeutics
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

0I3Q Stock 12 Month Forecast

Average Price Target

$141.00
▲(19.42% Upside)
Based on 5 Wall Street analysts offering 12 month price targets for Corcept Therapeutics in the last 3 months. The average price target is $141.00 with a high forecast of $165.00 and a low forecast of $50.00. The average price target represents a 19.42% change from the last price of $118.07.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"33":"$33","166":"$166","66.25":"$66.3","99.5":"$99.5","132.75":"$132.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":165,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$165.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":141,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$141.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":50,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$50.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[33,66.25,99.5,132.75,166],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2025","6":"Mar<br/>2026","9":"Jun<br/>2026","12":"Sep<br/>2026","25":"Sep<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,112.11,116.17846153846153,120.24692307692308,124.31538461538462,128.38384615384615,132.4523076923077,136.52076923076925,140.58923076923077,144.65769230769232,148.72615384615386,152.79461538461538,156.86307692307693,160.93153846153848,{"y":165,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,112.11,114.3323076923077,116.55461538461539,118.77692307692308,120.99923076923076,123.22153846153846,125.44384615384615,127.66615384615385,129.88846153846154,132.11076923076922,134.33307692307693,136.5553846153846,138.7776923076923,{"y":141,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,112.11,107.3323076923077,102.55461538461539,97.77692307692308,92.99923076923076,88.22153846153847,83.44384615384615,78.66615384615385,73.88846153846154,69.11076923076924,64.33307692307693,59.55538461538462,54.77769230769231,{"y":50,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":69.408,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":84.368,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":73.78,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":78.372,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":34.024,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":40.242,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":35.48,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":42.227,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":50.45,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":69.77,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":89.51,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":113.3,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":112.11,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$165.00Average Price Target$141.00Lowest Price Target$50.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Piper Sandler Analyst forecast on GB:0I3Q
David Amsellem
Piper Sandler
Piper Sandler
$165
Buy
39.75%
Upside
Reiterated
08/21/26
Analysts Offer Insights on Healthcare Companies: Corcept Therapeutics (NASDAQ: CORT), Alvotech (NASDAQ: ALVO) and Abbott Laboratories (NYSE: ABT)
Truist Financial Analyst forecast on GB:0I3Q
Srikripa Devarakonda
Truist Financial
Truist Financial
$50→$164
Buy
38.90%
Upside
Initiated
08/18/26
Corcept Therapeutics assumed with a Buy at TruistCorcept Therapeutics assumed with a Buy at Truist
Canaccord Genuity Analyst forecast on GB:0I3Q
Edward Nash
Canaccord Genuity
Canaccord Genuity
$161
Buy
36.36%
Upside
Reiterated
08/13/26
Canaccord Genuity Reaffirms Their Buy Rating on Corcept Therapeutics (CORT)
H.C. Wainwright Analyst forecast on GB:0I3Q
Swayampakula Ramakanth
H.C. Wainwright
H.C. Wainwright
$95→$165
Buy
39.75%
Upside
Reiterated
07/30/26
Corcept Therapeutics price target raised to $165 from $95 at H.C. WainwrightCorcept Therapeutics price target raised to $165 from $95 at H.C. Wainwright
Wolfe Research Analyst forecast on GB:0I3Q
Kalpit Patel
Wolfe Research
Wolfe Research
$50
Sell
-57.65%
Downside
Reiterated
07/29/26
Corcept: Strong Lifyorli Launch But Legal and Regulatory Risks Keep Sell Rating and $50 Price Target Unchanged
UBS Analyst forecast on GB:0I3Q
Ashwani Verma
UBS
UBS
$72
Buy
-39.02%
Downside
Upgraded
05/13/26
Corcept Therapeutics upgraded to Buy from Neutral at UBSCorcept Therapeutics upgraded to Buy from Neutral at UBS
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Piper Sandler Analyst forecast on GB:0I3Q
David Amsellem
Piper Sandler
Piper Sandler
$165
Buy
39.75%
Upside
Reiterated
08/21/26
Analysts Offer Insights on Healthcare Companies: Corcept Therapeutics (NASDAQ: CORT), Alvotech (NASDAQ: ALVO) and Abbott Laboratories (NYSE: ABT)
Truist Financial Analyst forecast on GB:0I3Q
Srikripa Devarakonda
Truist Financial
Truist Financial
$50→$164
Buy
38.90%
Upside
Initiated
08/18/26
Corcept Therapeutics assumed with a Buy at TruistCorcept Therapeutics assumed with a Buy at Truist
Canaccord Genuity Analyst forecast on GB:0I3Q
Edward Nash
Canaccord Genuity
Canaccord Genuity
$161
Buy
36.36%
Upside
Reiterated
08/13/26
Canaccord Genuity Reaffirms Their Buy Rating on Corcept Therapeutics (CORT)
H.C. Wainwright Analyst forecast on GB:0I3Q
Swayampakula Ramakanth
H.C. Wainwright
H.C. Wainwright
$95→$165
Buy
39.75%
Upside
Reiterated
07/30/26
Corcept Therapeutics price target raised to $165 from $95 at H.C. WainwrightCorcept Therapeutics price target raised to $165 from $95 at H.C. Wainwright
Wolfe Research Analyst forecast on GB:0I3Q
Kalpit Patel
Wolfe Research
Wolfe Research
$50
Sell
-57.65%
Downside
Reiterated
07/29/26
Corcept: Strong Lifyorli Launch But Legal and Regulatory Risks Keep Sell Rating and $50 Price Target Unchanged
UBS Analyst forecast on GB:0I3Q
Ashwani Verma
UBS
UBS
$72
Buy
-39.02%
Downside
Upgraded
05/13/26
Corcept Therapeutics upgraded to Buy from Neutral at UBSCorcept Therapeutics upgraded to Buy from Neutral at UBS
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
PTGXProtagonist Therapeutics
AXGNAxoGen
ATECAlphatec Holdings
CABACabaletta Bio
ONCBeOne Medicines
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Corcept Therapeutics

3 Months
Swayampakula RamakanthH.C. Wainwright
Success Rate
14/19 ratings generated profit
74%
Average Return
+23.13%
Copying Swayampakula Ramakanth's trades and holding each position for 3 Months would result in 73.68% of your transactions generating a profit, with an average return of +23.13% per trade.
1 Year
Edward NashCanaccord Genuity
Success Rate
28/34 ratings generated profit
82%
Average Return
+63.44%
Copying Edward Nash's trades and holding each position for 1 Year would result in 82.35% of your transactions generating a profit, with an average return of +63.44% per trade.
2 Years
Edward NashCanaccord Genuity
Success Rate
34/34 ratings generated profit
100%
Average Return
+110.94%
Copying Edward Nash's trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +110.94% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

0I3Q Analyst Recommendation Trends

Rating
May 26
Jun 26
Jul 26
Aug 26
Sep 26
Strong Buy
11
5
3
0
0
Buy
5
5
10
10
8
Hold
1
0
0
0
0
Sell
0
0
2
2
2
Strong Sell
0
0
0
0
0
total
17
10
15
12
10
In the current month, 0I3Q has received 8 Buy Ratings, 0 Hold Ratings, and 2 Sell Ratings. 0I3Q average Analyst price target in the past 3 months is 141.00.
Each month's total comprises the sum of three months' worth of ratings.

0I3Q Financial Forecast

0I3Q Earnings Forecast

Next quarter’s earnings estimate for 0I3Q is $0.81 with a range of $0.61 to $1.03. The previous quarter’s EPS was $0.36. 0I3Q beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year 0I3Q has Performed in-line its overall industry.
Next quarter’s earnings estimate for 0I3Q is $0.81 with a range of $0.61 to $1.03. The previous quarter’s EPS was $0.36. 0I3Q beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year 0I3Q has Performed in-line its overall industry.

0I3Q Sales Forecast

Next quarter’s sales forecast for 0I3Q is $323.90M with a range of $274.00M to $350.00M. The previous quarter’s sales results were $256.15M. 0I3Q beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year 0I3Q has Performed in-line its overall industry.
Next quarter’s sales forecast for 0I3Q is $323.90M with a range of $274.00M to $350.00M. The previous quarter’s sales results were $256.15M. 0I3Q beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year 0I3Q has Performed in-line its overall industry.

0I3Q Stock Forecast FAQ

What is GB:0I3Q’s average 12-month price target, according to analysts?
Based on analyst ratings, Corcept Therapeutics Inc.’s 12-month average price target is 141.00.
    What is GB:0I3Q’s upside potential, based on the analysts’ average price target?
    Corcept Therapeutics Inc. has 19.42% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is Corcept Therapeutics Inc. a Buy, Sell or Hold?
          Corcept Therapeutics Inc. has a consensus rating of Moderate Buy, which is based on 4 buy ratings, 0 hold ratings and 1 sell ratings.
            What is Corcept Therapeutics Inc.’s share price target?
            The average share price target for Corcept Therapeutics Inc. is 141.00. This is based on 5 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst share price target is $165.00 ,and the lowest forecast is $50.00. The average share price target represents 19.42% Increase from the current price of $118.07.
              What do analysts say about Corcept Therapeutics Inc.?
              Corcept Therapeutics Inc.’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 5 Wall Streets Analysts.
                How can I buy shares of Corcept Therapeutics Inc.?
                To buy shares of GB:0I3Q, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.